AstraZeneca subsidiary Alexion reaches definitive acquisition agreement with Lexington
ADC评论
October 4, 2022
On October 3, Alexion, a subsidiary of AstraZeneca’s rare disease business, announced that it had reached a definitive acquisition agreement with Lexington. The acquisition is
